AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05730517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CP5
Description: Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
Study NCT06236828 — intervention group
Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
Study NCT05729581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The educational programme on sustainable and healthy diet and breastfeeding
Description: In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
Study NCT05310526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Group
Description: Training for prescribing the Brazilian cardioprotective diet
Study NCT05436678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC 748 mg
Description: PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
Study NCT05436678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Ciprofloxacin
Study NCT05436678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib
Study NCT05710679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the potentiated radiotherapy in case of incomplete response (PET-CT)
Study NCT05584800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZGGS18 for Injection
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
Study NCT05584800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZGGS18 for Injection
Description: Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
Study NCT05595408 — intervention group
Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: cisplatin/carboplatin-gemcitabine 4-6 cycles
Study NCT05595408 — intervention group
Intervention type: DRUG
Intervention: adjuvant immunotherapy
Description: immunotherapy for one year
Study NCT05677230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon occluded/plug assisted retrograde transvenous obliteration.
Description: Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
Study NCT05677230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Obturation
Description: Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
Study NCT05753501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-101
Description: Oral:Tablet
Study NCT05330468 — intervention group
Intervention type: DEVICE
Intervention: Abbott Mechanical Heart Valve (MHV) Regent™
Description: SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
Study NCT05676476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Description: Antihypertensive treatment to goal of less than 140/90 mmHg
Study NCT05538091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
Study NCT05538091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
Study NCT06338618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver treatment protocol
Description: The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
Study NCT06344806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Breastfeeding Education
Description: Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
Study NCT04778787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Description: Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
Study NCT05523479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional online education
Description: A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
Study NCT05523479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional education
Description: Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
Study NCT05523479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical protocol
Description: An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices.
Study NCT05523479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
Study NCT05693545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxymethyl penicillin
Description: Prophylaxis
Study NCT05693545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular benzathine penicillin G (BPG) prophylaxis
Description: Prophylaxis
Study NCT05762055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan nanoLOCK interbody cage
Description: Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
Study NCT05762055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACDF interbody cage
Description: Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
Study NCT05523479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation HFNC for all eligible patients (without risk stratification)
Study NCT04984278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: oromucosal spray
Study NCT04984278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oromucosal spray
Study NCT06109376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypothermia
Description: In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
Study NCT06109376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
Study NCT06109376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thrombectomy
Description: Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
Study NCT06528145 — intervention group
Intervention type: OTHER
Intervention: Evalation
Description: Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
Study NCT05342493 — intervention group
Intervention type: DRUG
Intervention: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
Description: The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
Study NCT05914415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care and education before surgery
Description: we will give supportive and informative education before surgery in order to increase patient' recovery rates
Study NCT05914415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care and education before surgery
Description: we will give supportive and informative education before surgery in order to increase patient' recovery rates
Study NCT05863013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADL-Glittre Test
Description: They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
Study NCT05065697 — intervention group
Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
Study NCT01311414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cafedrine/theodrenaline, urapidil
Description: Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
Study NCT06212713 — intervention group
Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration - version older adults and informal caregivers
Study NCT05089604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Immediate Release, Oral
Description: Twice Daily Tacrolimus
Study NCT05089604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet
Description: Once Daily Tacrolimus
Study NCT06137534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern
Description: Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation.
Study NCT05370404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescription by surgical team
Description: The surgical team prescribes medications to the patient
Study NCT05370404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation by surgical team
Description: The surgical team recommends the patient to take over-the-counter medications
Study NCT03386604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
Study NCT03386604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin energy value 160 kcal.
Study NCT05079776 — intervention group
Intervention type: OTHER
Intervention: Physical length measurement
Description: Physical length will be measured and images will be collected for AI to estimate the length
Study NCT06365268 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
Study NCT06188104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test part one
Description: Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test part two
Description: Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1-minute sit-to-stand test
Description: Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4-meters gait speed test
Description: Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nailfold videocapillaroscopy
Description: Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HR-pQCT
Description: Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand x-ray
Description: Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
Study NCT04650659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA
Description: Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
Study NCT05853692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Three times a day (spray)
Study NCT05853692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Five times a day (rinse)
Study NCT06488885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Elderly care training
Description: The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
Study NCT04846816 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SQIN-01
Description: The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
Study NCT05016297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: baricitinib 4mg per day
Study NCT05016297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg twice a day
Study NCT05016297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg twice a day
Study NCT04230356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs) Scheduled
Description: VSTs will be infused into stem cell transplant recipients on schedule.
Study NCT04230356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs) Treatment
Description: VSTs will be infused into stem cell transplant recipients only if viremia is detected.
Study NCT05147701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT04908111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-MAGEA3-NYESO
Description: Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)